Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

202046 citationsJournal Articlegold Open Access

Authors

The two dosing regimens proposed for uncomplicated influenza did not achieve our pre-defined treatment threshold.

Good health and well-being

Published in: EBioMedicine

Volume 62, Issue 35, pp. 103125-103125

Field-Weighted Citation Impact: 5.09